Bringing microbial CDMO services to BIO International 2025 in Boston

Langenfeld, Germany – ARTES Biotechnology, the German-based biopharmaceutical CDMO for microbial cell lines and process development, will exhibit at the world’s premier biotechnology event, the BIO International Convention, this time in June in Boston, USA.

ARTES will be part of the German Pavilion at Location #3065 at the Boston Convention & Exhibition Center.

CDMO for microbial cell lines and processes

At BIO, ARTES will present its strengths in CDMO services. Of particular note are the various technology platforms for the development of microbial recombinant cell line and the process development for the production of various target products, including vaccines, biopharmaceuticals, biosimilars, and/or enzymes.

Another focus will be on the broad portfolio of pre-developed and therefore immediately transferable processes for enzymes, vaccines, and biosimilars.

Reliable and affordable services

The delegates from ARTES, Managing Director Dr. Michael Piontek and Business Development Director Dr. Melanie Piontek, will use the networking events at BIO to find new partnerships and applications for ARTES’ advanced capabilities.

ARTES´ team of expert scientists, engineers and technicians works in a lean, cost-effective structure. High quality standards deliver development reports and documentation as basis for our clients´ product registration with the relevant authorities.

Successful vaccine platforms

This is shown in a most recent project with Serum Institute of India. The R21/Matrix-M™ malaria vaccine launched in 2024 is the latest success story of ARTES vaccine technology and CDMO work. The vaccine platform enables efficient expression, folding and presentation of target antigens on the surface of chimeric VLPs. This improves recognition and uptake by antigen-presenting cells, leading to a strong immune response against the respective target antigen in the target organism.

At BIO International visitors are invited to get a closer look into the ARTES service portfolio.

About ARTES Biotechnology

ARTES Biotechnology GmbH is a German company specialized in the development of processes for the production of recombinant proteins from microbial expression systems. In particular, the company offers the development of optimized production cell lines and processes based on yeast (Hansenula, Pichia, Saccharomyces) and bacteria (E. coli). The expression platforms are complemented by a unique virus-like particle (VLP) technology for antigen presentation and vaccine development. For more than 20 years, ARTES has successfully partnered with human and animal health companies, enzyme manufacturers, and the cosmetics, diagnostics, and nutrition industries. The company operates worldwide from its 1,000 sqm facility in Langenfeld, Germany.

More information at http://www.artes-biotechnology.com

About BIO International 2025

The BIO International Convention is billed as the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech and now attracting almost 20,000 visitors from around the world. The convention provides an annual platform for biotechnology and pharma leaders to discover new opportunities and promising partnerships across a wide spectrum of life science and application areas, including drug discovery, biomanufacturing, genomics, nanotechnology and cell therapy.

Themed ‘The World Can’t Wait, the 32^nd BIO International Convention (BIO 2025) is a four-day event opening June 16, at the Boston Convention and Exhibition Center in Massachusetts.

BIO 2025 will host some 1,500 exhibitors alongside a week of intensive networking, and a conference featuring more than 135 sessions, organised in multiple tracks.

The event is organized by the Washington DC-based Biotechnology Innovation Organization with more information at: https://convention.bio.org/bio-2025

Resources

Click on ARTES Microbial Cell Line Development to learn more.
Click on ARTES Biotechnology Vaccines and Biopharmaceuticals to see introductory video.